Where can I buy Ikorituzumab?

Epcoritumab (Epcoritamab) is an innovative immunotherapy drug developed in recent years for B-cell-associated lymphomas (such as diffuse large B-cell lymphoma, follicular lymphoma, etc.) (non-Hodgkin lymphoma) . As a bispecific antibody, this drug can mobilize the immune system to attack tumor cells by targeting two molecules, CD3 and CD20, and has significant efficacy. In clinical application, icorelatumumab provides patients with a new option for the treatment of refractory or relapsed lymphoma, especially for patients who are ineffective with traditional treatments, providing new hope.

However, currently, icarelatumumab is not yet on the market in China, nor is it included in the medical insurance system, so its purchase channels in the country are relatively limited. If patients want to use the drug, they usually need to purchase it through international drug purchase channels, such as cross-border e-commerce platforms or through hospital drug import channels.

Overseas, icorituzumab has been approved and marketed, and patients can purchase the drug through local drug suppliers or through a doctor's prescription. In the United States and Europe, the drug is used to treat a variety of B-cell-related tumors, including diffuse large B-cell lymphoma, and has proven its good efficacy and tolerability in multiple clinical trials. When patients purchase icarelatumumab overseas, they need to use it under the guidance of a doctor to ensure the safety and efficacy of the drug.

Generally speaking, since icarelatumumab is not yet available in China, domestic patients need to purchase it overseas or participate in clinical trials to obtain the drug. During the treatment process, patients should fully communicate with their doctors to understand the indications, dosage and possible side effects of treatment to ensure the best treatment effect.

Reference materials:https://www.drugs.com/epcoritamab.html